First-in-Human Dose-Escalation Study of the First-in-Class PDE3A–SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A
Despite the decreased PDE3A enzymatic inhibition profile of BAY 2666605, the occurrence of thrombocytopenia in treated patients, an on-target effect of the compound, precluded the achievement of a therapeutic window, consequently leading to trial termination.
Authors
- Meredith McKean (ORCID: https://orcid.org/0000-0003-0944-7418)
- Silvia Goldoni
- Kyriakos P. Papadopoulos (ORCID: https://orcid.org/0000-0002-0667-2620)
- Christoph Kneip (ORCID: https://orcid.org/0000-0002-9386-9420)
- Gary Wilkinson (ORCID: https://orcid.org/0000-0003-1949-6205)
- Isabelle Genvresse
- Timothy Anthony Yap (ORCID: https://orcid.org/0000-0002-2154-3309)
- Marine F. Garrido
- Rui Li (ORCID: https://orcid.org/0000-0001-6516-6982)
Institutions
- Novartis (Switzerland) (CH)
- The University of Texas MD Anderson Cancer Center (US)
- Bayer (United States) (US)
- Urology San Antonio (US)
- Sarah Cannon (US)
- Agfa-Gevaert (Germany) (DE)
- Acceleron Pharma (United States) (US)
- Tennessee Oncology (US)
- Klinikum Leverkusen (DE)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-10-22
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-2713
- Citations
- 8
- Primary Topic
- Sexual function and dysfunction studies
- Type
- article
- Field-Weighted Citation Impact
- 3.08
Funders
- Bayer